Preventing stroke in atrial fibrillation: The SPORTIF programme

Pathophysiology of Haemostasis and Thrombosis

Volumn 34, Issue SUPPL. 1, 2005, Pages 25-30

  Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Non valvular atrial fibrillation; Oral direct thrombin inhibitors; Oral vitamin K antagonists; SPORTIF III; SPORTIF V; Stroke prevention; Warfarin; Ximelagatran

Indexed keywords

THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; DRUG SAFETY; DRUG SCREENING; EMBOLISM; HEALTH PROGRAM; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MONITORING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; TREATMENT OUTCOME; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; WARFARIN;

EID: 20844447979     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083081     Document Type: Review

References (26)

1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro JM, Beiser A, Wolf PA, Benjamin EJ: Lifetime risk for development of atrial fibrillation: The Framingham Heart Study. Circulation 2004;110:1042-1046.
2. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-988.
3. Hart RG, Halperin JL: Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. Ann Intern Med 1999;131: 688-695.
4. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch Intern Med 1998;158:1316-1320.
5. Wolf PA, Mitchell JB, Baker CS, Kannel WB, D'Agostino RB: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-234.
6. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
7. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG: ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-1923.
8. Lip GYH, Hart RG, Conway DS: Antithrombotic therapy for atrial fibrillation. Br Med J 2002;325:1022-1025.
9. Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994;154:1443-1448.
10. Gottlieb LK, Salem-Schatz S: Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.
11. Lip GYH, Tean KN, Dunn FG: Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994;71:92-95.
12. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA: Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-1171.
13. Casey M, Hanley K: A measurement of the efficacy of anticoagulation monitoring in a general practice based setting. Ir Med J 2001;94: 245-246.
14. Brophy MT, Snyder KE, Gaehde S, Ives C, Gagnon D, Fiore LD: Anticoagulant use for atrial fibrillation in the elderly. J Am Geriatr Soc 2004;52:1151-1156.
15. Hylek EM, Skates SJ, Sheehan MA, Singer DE: An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-546.
16. The Stroke Prevention in Atrial Fibrillation Investigators: Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996;156:409-416.
17. Wells PS, Holbrook AM, Crowther NR, Hirsh J: Interactions of warfarin with drugs and food. Ann Intern Med 1994;121:676-683.
18. Williams E, Ansari M, Lip GY: Managing atrial fibrillation in the Accident and Emergency department. QJM 2001;94:609-614.
19. Lip GYH, Zarifis J, Watson RD, Beevers DG: Physician variation in the management of patients with atrial fibrillation. Heart 1996;75:200-205.
20. Lip GYH, Kamath S, Jafri M, Mohammed A, Bareford D: Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: The West Birmingham Atrial Fibrillation Project. Stroke 2002;33:238-242.
21. Halperin JL: Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003;146:431-438.
22. The Executive Steering Committee on behalf of the SPORTIF III Investigators: Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet 2003;362:1691-1698.
23. The Executive Steering Committee on behalf of the SPORTIF V Investigators: Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation (SPORTIF V). Circulation 2003;108(supplement):2723 (J).
24. Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.
25. Halperin JL for the Executive Steering Committee on behalf of the SPORTIF V investigators. Stroke prevention using the oral thrombin inhibitor ximelagatran in patients with atrial fibrillation (SPORTIF V). American Heart Association. Orlando, Florida, 9-12 November 2003.
26. Albers GW on behalf of the SPORTIF Investigators. Ximelagatran, an oral direct thrombin inhibitor, compared with dose-adjusted warfarin for primary and secondary stroke prevention in patients with AF. American Academy of Neurology. San Francisco, California. Oral presentation available at http://strokecenter. stanford.edu/docs/AAN04_SP_V_final.ppt [accessed October 2004], 24 April-1 May 2004.